Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
desktop iconMarkt Monitor

Aandeel Galapagos BE0003818359

Laatste koers (eur) Verschil Volume
24,940   -0,040   (-0,16%) Dagrange 24,940 - 25,760 90.453   Gem. (3M) 119,3K

KOERS GALAPAGOS 2015

16.480 Posts
Pagina: «« 1 ... 239 240 241 242 243 ... 824 »» | Laatste | Omlaag ↓
  1. [verwijderd] 30 april 2015 08:58
    It's Georgia based but this is from their Dublin bureau:

    The data keep filgotinib on track for a pivotal program, be it with or without Abbvie, which has to decide whether to stick with its own, earlier-stage JAK inhibitor ABT-494 or to shell out for a program that now has far less risk attached. The progress of baricitinib, a phase III dual JAK1/JAK2 inhibitor that Incyte Inc., of Wilmington, Del., is co-developing with Eli Lilly and Co., of Indianapolis, will likely loom large in its decision-making progress.

    www.bioworld.com/content/galapagos-ja...

    not new but still interesting to read this again.
16.480 Posts
Pagina: «« 1 ... 239 240 241 242 243 ... 824 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.